Please assess the completion status of the following clinical trial:

Trial Title: Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 4 to \< 7 years on the day of inclusion~* Informed consent form has been signed and dated by the parent/guardian before the first study-related procedure~* Subject and parent/guardian are able to attend all scheduled visits and to comply with all trial procedures~* Subject has documented completion of primary infant series and booster with DAPTACEL® and/or Pentacel® vaccine(s) only.~Exclusion Criteria:~* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination~* Planned participation in another clinical trial during the present trial period~* Receipt of any vaccine in the 4 weeks preceding the trial vaccination, except for any influenza vaccine, which may be received at least 2 weeks before study vaccines~* Planned receipt of any vaccine in the 4 weeks following the trial vaccination except for any influenza vaccine, which may be received at least 2 weeks after study vaccines~* Receipt of blood or blood-derived products in the past 3 months~* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)~* History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~* History of diphtheria, tetanus, or pertussis infection, confirmed either clinically, serologically, or microbiologically~* Known systemic hypersensitivity to any of the vaccines' components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances~* Laboratory-confirmed thrombocytopenia, contraindicating intramuscular vaccination~* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination~* Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion~* Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the investigator.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- Study Group 1 (Type: EXPERIMENTAL): Participants will receive concomitantly a dose of DTap-IPV, a dose of M-M-R®II, and a dose of VARIVAX® vaccine on Day 0
- Study Group 2 (Type: EXPERIMENTAL): Participants will receive concomitantly a dose of DAPTACEL®, a dose of IPOL®, a dose of M-M-R®II, and a dose of VARIVAX® vaccines on Day 0
- Study Group 3 (Type: EXPERIMENTAL): Participants will receive concomitantly a dose of DTap-IPV with or without a dose of M-M-R®II and a dose of VARIVAX® on Day 0
- Study Group 4 (Type: EXPERIMENTAL): Participants will receive concomitantly a dose of DAPTACEL® vaccine, a dose of IPOL® vaccine with or without a dose of M-M-R®II and a dose of VARIVAX® vaccines on Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete